ID	DisplayName	Authors	Year	Title	Publication	PublicationLocation	WebLink
Pawlotsky_2016	Pawlotsky, 2016	Pawlotsky, J-M	2016	Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens	Gastroenterology	151(1):70-86	http://www.sciencedirect.com/science/article/pii/S0016508516300555
Sarrazin_2016	Sarrazin, 2016	Sarrazin, C	2016	The importance of resistance to direct antiviral drugs in HCV infection in clinical practice	Journal of Hepatology	64(2):486-504	http://www.sciencedirect.com/science/article/pii/S0168827815006297
Lontok_et_al_2015	Lontok et al., 2015	Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V	2015	Hepatitis C virus drug resistance-associated substitutions: State of the art summary	Hepatology	62(5):1623-32	http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/abstract;jsessionid=657E6E3C85196C806137825E68AA9660.f02t01
Lawitz_et_al_2016	Lawitz et al., 2016	Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R and Witek J.	2016	Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)	Hepatology	64(2):360-9	http://onlinelibrary.wiley.com/doi/10.1002/hep.28422/abstract
Foster_et_al_2015	Foster et al., 2015	Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators	2015	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection	New England Journal of Medicine	373(27):2608-17	http://www.nejm.org/doi/full/10.1056/NEJMoa1512612